Novo Nordisk Presents Semaglutide MASH Data at EASL 2026 Across Three Patient Subgroups

Novo Nordisk's expanding MASH indication for semaglutide 2.4 mg is moving from Phase 3 confirmation into the subgroup-evidence phase that regulators typically require before broad-label approval — a signal that a formal submission strategy is taking shape. At EASL Congress 2026 (27–30 May, Barcelona), the company is presenting multiple new analyses from the ESSENCE Phase 3 programme, each extending the clinical dataset into populations that historically carry disproportionate regulatory scrutiny.

The ESSENCE Liver Safety analysis (Newsome et al.) addresses a foundational concern for any hepatic indication: treatment-emergent hepatotoxicity risk in a population with already-compromised liver function. The data demonstrate a favourable hepatic safety profile for semaglutide 2.4 mg across patient subgroups, independent of baseline characteristics — a finding that QA and regulatory teams will need to map against ICH E8 subgroup adequacy expectations in any forthcoming submission dossier.

Two additional subgroup analyses extend the evidence base in directions regulators and health technology assessment bodies increasingly require. The ESSENCE Menopause subgroup (Abdelmalek et al.) generates dedicated data for postmenopausal women, a cohort in whom accelerated fibrosis progression is documented but who have been systematically underrepresented in MASH trials. The ESSENCE Japanese subgroup (Nakajima et al.) addresses MASLD and MASH at lower body-weight thresholds characteristic of Asian populations — directly relevant to submissions under PMDA jurisdiction and to ICH E5 bridging requirements.

The disease context sharpens the manufacturing and supply implications. MASH affects an estimated 250 million people globally, with approximately nine in ten cases currently undiagnosed. As diagnostic rates improve alongside any approved pharmacological option, the addressable patient population could expand rapidly and non-linearly — a demand-forecasting variable that plant heads and supply-chain leads will need to model against existing semaglutide fill-finish capacity, which has already been under pressure from the obesity indication.

Real-world evidence presented alongside the clinical analyses documents significant quality-of-life impairment and elevated healthcare utilisation in MASH patients, reinforcing the payer and health-system pressure that typically accelerates regulatory review timelines. For regulatory affairs leads tracking the GLP-1 receptor agonist class, the ESSENCE subgroup portfolio represents the kind of population-level evidence package that supports label language beyond the primary trial population.

The completeness of the ESSENCE subgroup dataset presented at EASL 2026 will be a measurable checkpoint when Novo Nordisk's MASH submission dossier enters formal agency review.

Source: Novo Nordisk via GlobeNewswire, 19 May 2026.